Edition:
India

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

32.20EUR
17 Aug 2018
Change (% chg)

€0.72 (+2.29%)
Prev Close
€31.48
Open
€31.58
Day's High
€32.48
Day's Low
€31.58
Volume
77,898
Avg. Vol
76,058
52-wk High
€86.64
52-wk Low
€28.54

Chart for

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

Beta: 0.44
Market Cap(Mil.): €1,956.98
Shares Outstanding(Mil.): 24.10
Dividend: --
Yield (%): --

Financials

  DBV.PA Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -5.32 -- --
ROI: -54.08 15.07 14.61
ROE: -57.09 16.59 16.33

BRIEF-DBV Technologies Reports Cash position of 234.5 Million Euros at end March

* CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018, WERE EUR 234.5 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

27 Apr 2018

BRIEF-DBV Technologies: Closing Of Underwriters' Option To Purchase Additional Shares In Global Offering

* REG-DBV TECHNOLOGIES ANNOUNCES CLOSING OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES IN GLOBAL OFFERING

27 Mar 2018

BRIEF-DBV Technologies Announces Pricing Of 122.5 Million Euros Global Offering Of Ordinary Shares

* ANNOUNCES PRICING OF $150.0 MILLION (EUR 122.5 MILLION) GLOBAL OFFERING OF ORDINARY SHARES

21 Mar 2018

BRIEF-DBV Technologies ‍Announces Intention To Issue And Sell Up To $150 Mln Of New Ordinary Shares​

* DBV TECHNOLOGIES ANNOUNCES THE LAUNCH OF A PROPOSED GLOBAL OFFERING OF ORDINARY SHARES, WHICH MAY BE IN THE FORM OF AMERICAN DEPOSITARY SHARES

21 Mar 2018

BRIEF-DBV Technologies FY Net Loss widens to 147.7 Million Euros

* CASH AND CASH EQUIVALENTS AS OF DEC 31, 2017 EUR 137.9 MILLION VERSUS EUR 256.5 MILLION YEAR AGO

14 Mar 2018

BRIEF-DBV Technologies Announces Result From Phase II Study of Viaskin Milk

* ANNOUNCED ON MONDAY, RESULT FROM PHASE II STUDY OF VIASKIN MILK IN MILK-ALLERGIC PATIENTS

27 Feb 2018

BRIEF-DBV Technologies Announces Results From Phase II Study Of Viaskin Milk In Milk-Allergic Patients

* DBV TECHNOLOGIES ANNOUNCES RESULTS FROM PHASE II STUDY OF VIASKIN MILK IN MILK-ALLERGIC PATIENTS

27 Feb 2018

BRIEF-DBV Technologies Cash And Cash Equivalents At Dec. 31 Down At 137.9 Million Euros

* ‍CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017, WERE EUR 137.9 MILLION, VERSUS EUR 256.5 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

20 Feb 2018

Earnings vs. Estimates